Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Acquisitions & Divestments: 2016-2025

Historic Change in Acquisitions & Divestments for Tg Therapeutics (TGTX) over the last 3 years, with Sep 2025 value amounting to $77.8 million.

  • Tg Therapeutics' Change in Acquisitions & Divestments fell 15.76% to $77.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.2 million, marking a year-over-year increase of 7.79%. This contributed to the annual value of $310.9 million for FY2024, which is 223.08% up from last year.
  • Tg Therapeutics' Change in Acquisitions & Divestments amounted to $77.8 million in Q3 2025, which was up 57.55% from $49.4 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Change in Acquisitions & Divestments peaked at $92.3 million during Q3 2024, and registered a low of $16.0 million during Q1 2023.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $71.5 million (2024), whereas its average is $55.9 million.
  • As far as peak fluctuations go, Tg Therapeutics' Change in Acquisitions & Divestments skyrocketed by 358.76% in 2024, and later plummeted by 30.98% in 2025.
  • Over the past 4 years, Tg Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $20.3 million in 2022, then increased by 16.81% to $23.7 million in 2023, then surged by 211.26% to $73.7 million in 2024, then declined by 15.76% to $77.8 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $77.8 million for Q3 2025, versus $49.4 million for Q2 2025 and $80.4 million for Q1 2025.